Trials / Completed
CompletedNCT02257424
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/II Open-Label Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trametinib 2 mg daily | |
| DRUG | hydroxychloroquine (HCQ) | hydroxychloroquine (HCQ) is 600 mg orally every 12 hours |
| DRUG | dabrafenib 150 mg orally twice a day |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2021-10-01
- Completion
- 2021-10-01
- First posted
- 2014-10-06
- Last updated
- 2022-01-20
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02257424. Inclusion in this directory is not an endorsement.